Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REALYSE - Comparative Effectiveness of Once-daily Oral Semaglutide Versus Any Other Oral Glucose-lowering Medication in a Real-world Adult Population With Type 2 Diabetes on Metformin Monotherapy in US Based Health Care Systems - a Pragmatic Randomized Trial

NCT05035082 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05035082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05035082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REALYSE - Comparative Effectiveness of Once-daily Oral Semaglutide Versus Any Other Oral Glucose-lowering Medication in a Real-world Adult Population With Type 2 Diabetes on Metformin Monotherapy in US Based Health Care Systems - a Pragmatic Randomized Trial
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
September 1, 2021
Completion date
June 18, 2025
Enrollment
1,018 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2